Brief: BioXcel Therapeutics Q3 Basic EPS USD -2.18 Vs. IBES Estimate USD -1.24
12/11/2025 12:00
Nov 12 (Reuters) - BioXcel Therapeutics Q3 net income USD -30.911 million vs. IBES estimate USD -14.1 million. Q3 operating expenses USD 14.326 million Q3 operating income USD -14.228 million vs. IBES estimate USD -11.4 million Q3 revenue USD 98 thousand vs. IBES estimate USD 216 thousand
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty